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Background: Previous studies of patients with “lone” and “idiopathic” atrial ﬁbrillation (AF) have provided
conﬂicting evidence concerning the development, management and prognosis of this condition.
Methods: In this nation-wide, retrospective, cohort study, we studied patients diagnosed with incidental AF
recorded in national Swedish registries between 1995 and 2008. Controlswerematched for age, sex and calendar
year of the diagnosis of AF in patients. All subjects were free of any in-hospital diagnosis from 1987 and until
patients were diagnosed with AF and also free of any diagnosis within one year from the time of inclusion.
Follow-up continued until 2009. We identiﬁed 9519 patients (31% women) and 12,468 matched controls.
Results: Relative risks (RR) versus controls for stroke or transient ischemic attack (TIA) in womenwere 19.6, 4.4,
3.4 and 2.5 in the age categories b55, 55−64, 65−74 and 75−85, years respectively. Corresponding ﬁgures for
men were 3.4, 2.5, 1.7 and 1.9. RR for heart failure were 6.6, 6.6, 6.3 and 3.8 in women and 7.8, 4.6, 4.9 and 2.9 in
men. All RRwere statistically signiﬁcant with p b 0.01. RR for myocardial infarction and all-cause mortality were
statistically signiﬁcantly increased only in the two oldest age categories in women and 65−74 years in men.
Conclusions: Patients with AF and no co-morbidities at inclusion had at least a doubled risk of stroke or TIA and a
tripled risk of heart failure, through all age categories, as compared to controls. Women were at higher RR of
stroke or TIA than men.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under theCCBY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Atrial ﬁbrillation (AF) has been reported to be an independent
risk factor of death and morbidity [1]. The mortality risk increases
in the presence of co-morbidities, while AF in patients without co-
morbidities has been considered relatively harmless, possibly because
this arrhythmia is often found in younger individuals [1,2]. The number
of patients with AF without co-morbidities is dependent on the
deﬁnition of the study populations, but there is as yet no study on theability and freedom from bias of
Örebro University Hospital, 701
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land Ltd. This is an open access articlelong-term course of a very large cohort of patients and controls with
this condition.
Patients below 60 years of age have been considered to have lone AF
if they have no evidence of cardiopulmonary disease, while idiopathic
AF requires the absence of any other disease, irrespective of age [1,3].
However, the deﬁnitions of lone and idiopathic are heterogeneous, the
age criterion has been questioned and the studied populations have
been small or have lacked controls free from AF [4–12].
A statistically signiﬁcant increase in all-cause mortality has only
been found in one study of patients with lone or idiopathic AF
(Table 1) [5,6,8,11,12]. Previous studies of heart failure in the general
population have shown an increased prevalence in men compared to
women and that patients with AF have an increased risk of heart failure
[1,2,11,13–15]. However, studies with 41 to 76 patients with lone or
idiopathic AF have not shown any statistically signiﬁcantly increasedunder the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Table 1
Studies of lone or idiopathic atrial ﬁbrillation with controls.
First author N Controls Age-mean
(years)
Follow-up
(years)
Stroke/TIA Heart
failure
Myocardial
infarction
All-cause
mortality
Combined
endpoint
Brand et al [4] 43 Age–sex matched 70.6 (men)
68.1 (women)
30 0.9% vs 0.2%a
(p b 0.01)
ns ns (coronary
heart disease)
–
Jouven et al [5] 25 Age–sex matched 47.6 23 – – – RR 1.95 (p = 0.02)
Jangahir et al [6] 76 Age–sex speciﬁed incidence rates 44.2 30 0.9% vs 0.5%a
(p = 0.004)
ns – ns
Weijs et al [7] 41 Age–sex matched 58 5.5 (mean) ns ns ns ns 8.9% vs 3.6% a,b
(p = 0.006)
Kopecky et al [8] 97 Life-table analysis and difference
between isolated, recurrent and
chronic AF
44.0 14.8 (mean) Lowc – Lowc ns
Stewart et al [11] 15 Age–sex matched d 20 – – – ns nse
Kopecky et al [12] 55 Age–sex matched 74 9.6 (median) 2.0% vs 0.2%a
(p b 0.01)
– 2.6% vs 1.1%a
(p = 0.02)
ns 5.0% vs 1.3%a,f
(p b 0.01)
Abbrevations: N, numbers of patients; TIA, transient ischemic attack; ns, not statistically signiﬁcant; RR, relative risk; vs, versus; y, years.
a Annual rates in percentage.
b Cardiovascular death, myocardial infarction, cerebrovascular accident, heart failure, coronary artery disease and new onset hypertension.
c Conﬁrmed low incidence.
d Age not speciﬁed in subgroup of patients with lone atrial ﬁbrillation.
e Cardiovascular hospitalization and death.
f Stroke, transient ischemic attack, myocardial infarction, valvular heart disease, coronary heart disease and cardiac surgery.
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disease in these patients [4,6,7,12]. Cohorts of 43 to 76 patients with
lone or idiopathic AF had an increased risk of stroke with annual rates
between 0.9% and 2.0%, and equal rates between in men and women
have been found [4,6,12].
National health registries in Sweden record the discharge diagnoses
of all hospitalized patients and provide high quality information [16,17].
Personal identiﬁcation numbers allow comprehensive coverage of all
non-emigrated patients throughout life. Due to the all-inclusive nature272,186 patients with inci
between 1995 a
544,344 matched controls w
9519 patien
12,468 matche
14,603 patients without other
in-hospital diagnoses since 1987
and during the first year of follow-up
257,583 patients with other
in-hospital diagnoses since 1987
and during the first year of
follow-up
5084 patients without
matched controls
Fig. 1. Flowchart of patients with incident atrial ﬁbrillatof the information recorded in the registries, it is possible to obtain a na-
tional estimate of long-term cardiovascular risks. The registries are well
established and allow researchers to make retrospective analyses in
large patient cohorts, and they permit the performance of prospective
nationwide randomized trials [2,18–20].
Our purpose was to estimate the risk of stroke or transient ischemic
attack, heart failure, myocardial infarction and all-cause mortality in all
patients hospitalized with incident AF as the only diagnosis and in
matched controls in a comprehensive nation-wide study.dent atrial fibrillation
nd 2008 and
ithout atrial fibrillation
ts and
d controls
495,263 controls with other
in-hospital diagnoses since 1987
and during the first year of
follow-up
49,081 controls without other
in-hospital diagnoses since 1987
and during the first year of follow-up
36,613 controls without 
matched patients
ion and matched controls without other diagnoses.
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2.1. Study design and national registries
We conducted a nationwide, retrospective controlled cohort study
using the Swedish National Patient Registry, the General Population
Registry and the Cause of Death Registry. The study cohort was identi-
ﬁed by the epidemiological centre at the Swedish National Board of
Health and Welfare, and the matching procedure was carried out by
Statistics Sweden. The Swedish National Patient Registry has a N99%
coverage of hospital diagnoses from 1987 and onwards, and the diagno-
ses have a positive predictive value of 85−95% [16]. Although some
conditions that are generally managed on an outpatient basis, such as
hypertension, is known to be somewhat underreported, the validity
of the registry is high andhas therefore been proposed to be used for ep-
idemiological studies by the National Board of Health and Welfare
[16,17]. In Sweden, all inhabitants have a unique personal identiﬁcation
number, all have equal access to health care and hospital services, and
hospitals are required to record all discharge diagnoses. This provides
the possibility to record and track all non-emigrated patients in clinical
registries and analyze morbidity and mortality in the entire Swedish
population. This study complied with the Declaration of Helsinki, and
the study protocol was approved by the Regional Ethical Review
Board in Uppsala, Sweden (Dnr 2009/273).Fig. 2. A-2D Risk of stroke and transient ischemic attack in patients with atri2.2. Study population and deﬁnitions of patients, controls, outcome and
follow-up
Patients were eligible if they had a diagnosis of incident AF between
1995 and 2008 and no diagnosis of AF between 1987 and 1994, thus
making it likely that the AFwas truly incident. AFwas deﬁned according
to the International Classiﬁcation of Diseases (ICD): 427 D (DA, DB, DC,
DD, DW) in ICD 9 (1987−1996) and I 48, I48.9 and I 48.9 (A, B, C, D, E, F,
P, X) in ICD 10 (1997 – 2011). No distinction could be made between
paroxysmal, persistent or permanent AF, and atrial ﬂutter. To identify
patients with incident AF without other diseases, the National Patient
Registry was used to exclude patients with other in-hospital diagnoses
from 1987 until the time of inclusion. All diagnoses from ICD 9
(001−999) and 10 (A00−Z99)were excluded: thus, included patients
only had a single diagnosis of AF. In the event of re-hospitalization with
any in-hospital diagnosis or death within one year from the time of the
incident AF, such patients were excluded in order to increase the likeli-
hood that subsequent events were due to AF and not to an undetected
developing cardiovascular condition.
For each patientwith AF, one or two controlswith nohospital record
of AF between 1987 and 2009 were selected and matched for age, sex
and calendar year of the diagnosis of AF by linkage with the General
Population Registry. First-degree relatives of patients with AF were
not included as controls. Diagnoses that were excluded since 1987al ﬁbrillation and controls without other diagnoses in all age categories.
Table 2
Annual stroke and mortality rate in patients with atrial ﬁbrillation and controls without
other diagnoses with corresponding risk scores from CHA2DS2-VASc and CHADS2 divided
into sex and age categories.
CHA2DS2-VASc CHADS2 Annual stroke
rate (%)
Annual mortality
rate (%)
Patients Controls Patients Controls
Women
b55 1 0 0.5 0.0 0.2 0.3
55–64 1 0 1.1 0.3 0.5 0.5
65–74 2 0 2.1 0.6 1.7 1.3
75–85 3 1 3.9 1.5 5.0 3.6
Men
b55 0 0 0.3 0.1 0.2 0.2
55–64 0 0 1.0 0.4 0.7 0.7
65–74 1 0 1.6 0.9 2.3 2.0
75–85 2 1 3.3 1.7 5.9 5.1
Abbrevations: CHA2DS2-VASc = Cardiac failure, Hypertension, Age ≥ 75 (doubled),
Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex category (female).
CHADS2 = Cardiac failure, Hypertension, Age ≥75, Diabetes, and Stroke (doubled).
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alive on January 1st in the year of the diagnosis of the index patient. If
a control person had died earlier related to the index patient during
the ﬁrst year, the time at risk was set to one day.
During follow-up, the classiﬁcations from the ICD 9 and 10 were:
stroke and transient ischemic attack, 433 (A, B, C, D, W, X), 434 (A, B,
X), 435, I 63 (0, 1, 2, 3, 4, 5, 6, 8, 9), I 64 and G 45 (0, 1, 2, 3, 4, 8, 9);
heart failure, 428 (A, B, X) and I 50 (0, 1, 9); myocardial infarction, 410
(A, B, W, X), 411 (A, B, C, X), 412, I 21 (0, 1, 2, 3, 4, 9), I 22 (0, 1, 8, 9)
and I 25.2. The risks of an in-hospital diagnosis were assessed from the
date of inclusion to the date when such a diagnosis was registered, a pa-
tient died or emigrated, or to the end of follow-up on 31December 2009.
The original cohort consisted of 272,186 patients with incident AF
between 1995 and 2008. There were 9519 patients with incident AFTable 3
Rates, events and hazard ratios of cardiovascular morbidity and all-cause mortality in patients
Age category Women Me
AF patients Controls AF patients vs. controls AF
Ratesa Events Ratesa Events HR (95 % CI) Ra
Stroke and TIA
b55 5.0 14 0.2 1 19.6 (2.6−149.2) 2
55−64 10.5 61 2.4 19 4.4 (2.6−7.3) 10
65−74 21.1 194 6.2 78 3.4 (2.6−4.5) 16
75−85 38.3 210 15.6 111 2.5 (2.0−3.2) 33
Totalb 3.1 (2.6−3.7)
Heart failure
b55 5.0 14 0.8 3 6.6 (1.9−23.1) 2
55−64 10.4 61 1.6 13 6.5 (3.6−11.8) 8
65−74 19.9 186 3.3 42 6.3 (4.5−8.8) 20
75−85 40.2 222 11.4 84 3.8 (2.9−4.8) 45
Totalb 4.8 (4.0−5.8)
Myocardial infarction
b55 1.4 4 1.3 5 1.1 (0.3−4.2) 2
55−64 4.0 24 2.6 21 1.5 (0.8−2.7) 5
65−74 9.1 88 4.9 62 1.9 (1.4−2.6) 12
75−85 14.3 84 9.5 70 1.5 (1.1−2.1) 18
Totalb 1.6 (1.3−2.0)
All-cause mortality
b55 3.5 10 3.3 13 1.1 (0.5−2.4) 2
55−64 6.2 38 6.1 49 1.0 (0.7−1.6) 8
65−74 20.7 207 15.0 192 1.4 (1.2−1.7) 27
75−85 57.3 351 40.2 302 1.5 (1.3−1.7) 64
Totalb 1.4 (1.3−1.6)
Abbrevations: AF, atrial ﬁbrillation; HR, hazard ratio; Rates, incidence rates per 1000 person-ye
a Rates per 1000 person-years.
b Hazard ratio adjusted by age at diagnosis in ﬁve year intervals from b55 years.and 12,468 matched controls without in-hospital diagnoses since
1987 and during the ﬁrst year after inclusion (Fig. 1).
2.3. Statistical analysis
Continuous variableswere summarizedwithmean and standard de-
viations (SD) and categorical percentages. Unadjusted Kaplan−Meier
plots were used to calculate the cumulative probability of stroke and
transient ischemic attack, heart failure, myocardial infarction and
all-causemortality. Rates of diseaseswere deﬁned as the number of per-
sons with the speciﬁc disease and mortality rates as the number of
deaths, which were divided by the number of person-years at risk.
The annual rates were then calculated by dividing the ten-year rate
with ten. Cox regression models were used to compare patients with
AF and controls, adjusted by age at diagnosis and categorized into
ﬁve-year age bands, with the ﬁrst category younger than 55 years,
and modelled as a categorical variable. Separate regression models
were estimated for men and women combined with age categories at
diagnosis of: younger than 55, 55–65, 65–74 and 75–85 years of age.
Cox regression was also used to compare women and men with AF. To
measure associations, we used hazard ratios as estimates of relative
risks accompanied with 95% conﬁdence intervals (CI). All statistical
calculationsweremadewith STATA release 11 software (StataCorp, Col-
lege Station, TX, USA), and two-sided P values of b0.05were considered
statistically signiﬁcant.
3. Results
3.1. Baseline characteristics
There were 9519 patients and 12,468 matched controls in our
study cohort (Fig. 1). The mean age was higher in women than men,
67.7 ± 10.4 years vs. 54.9 ± 13.4 years (p b 0.01). The proportion of
women was 9% in the age category younger than 55 years, 26% atwith atrial ﬁbrillation without other diagnoses, speciﬁed in sex and age categories.
n AF patients
patients Controls AF patients vs. controls Women vs. men
tesa Events Ratesa Events HR (95 % CI) HR (95 % CI)
.9 74 0.9 32 3.4 (2.2−5.2) 1.67 (0.94−2.95)
.1 151 4.1 84 2.5 (1.9−3.2) 1.00 (0.74−1.34)
.1 147 9.7 112 1.7 (1.3−2.1) 1.25 (1.01−1.56)
.7 85 17.5 53 1.9 (1.4−2.7) 1.11 (0.86−1.43)
2.2 (1.8−2.5) 1.16 (1.01−1.34)
.9 74 0.4 14 7.8 (4.4−13.8) 1.60 (0.90−2.84)
.5 130 1.9 39 4.6 (3.2−6.6) 1.15 (0.84−1.56)
.7 191 4.4 52 4.9 (3.6−6.6) 0.88 (0.72−1.08)
.6 113 16.1 50 2.9 (2.0−4.0) 0.84 (0.67−1.06)
4.4 (3.7−5.3) 0.94 (0.82−1.07)
.0 51 1.7 62 1.2 (0.8−1.7) 0.66 (0.24−1.84)
.7 87 5.3 110 1.1 (0.8−1.4) 0.66 (0.42−1.04)
.4 116 8.9 103 1.4 (1.1−1.8) 0.68 (0.51−0.90)
.7 49 17.5 54 1.1 (0.7−1.6) 0.74 (0.52−1.06)
1.2 (1.0−1.4) 0.70 (0.57−0.84)
.4 62 2.1 78 1.2 (0.8−1.6) 1.32 (0.68−2.58)
.5 133 7.6 161 1.1 (0.9−1.4) 0.65 (0.45−0.93)
.3 267 22.2 267 1.2 (1.0−1.5) 0.67 (0.56−0.81)
.5 179 56.5 181 1.1 (0.9−1.4) 0.81 (0.68−0.97)
1.2 (1.0−1.3) 0.74 (0.66−0.84)
ars; Events, numbers of actual cases; TIA, transient ischemic attack.
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total cohort.
3.2. The incidence and risk of stroke or transient ischemic attack during
follow-up
The annual rates of stroke and transient ischemic attack in women
were 0.5%, 1.1%, 2.1% and 3.9% in age categories b55, 55-64, 65–74
and 75–85 years and 0.0%, 0.3%, 0.6% and 1.5% in the corresponding con-
trols (Fig. 2A–D). In men, the corresponding rates were 0.3%, 1.0%, 1.6%
and 3.3% in patients with AF and 0.1%, 0.4%, 0.9% and 1.7% in controls
(Table 2). AF was strongly associated with the occurrence of stroke
and transient ischemic attack in all age categories and both sexes, and
the difference versus matched controls was statistically signiﬁcant
(Table 3). The relative risk in patients versus controls was tripled in
women and doubled in men. In female compared to male patients, the
incidence rates were statistically signiﬁcantly higher overall and in the
age category 65–74 years.
3.3. The incidence and risk of heart failure during follow-up
The annual rates of heart failure in womenwere 0.5%, 0.9%, 1.8% and
3.7% in age categories b55, 55–64, 65–74 and 75–85 years and 0.0%,
0.1%, 0.3% and 1.0% in controls (Fig. 3A–D). In men, the correspondingFig. 3. A-3D risk of heart failure in patients with atrial ﬁbrillationrates were 0.3%, 0.8%, 1.9% and 4.3% in patients and 0.0%, 0.2%, 0.4%
and 1.5% in controls. AF was strongly associated with an increased risk
of heart failure in all age categories and both sexes, and the risks were
statistically signiﬁcant compared with matched controls (Table 3).
Overall, the relative riskwas almost ﬁvefold inwomen and at least four-
fold in men. The incidence rates in patients with AF were comparable
between women and men in all age categories.3.4. The incidence and risk of myocardial infarction during follow-up
The annual rates of myocardial infarction in womenwere 0.2%, 0.4%,
0.8% and 1.4% in age categories b55, 55–64, 65–74 and 75–85 years
and 0.1%, 0.2%, 0.5% and 0.9% in controls (Fig. 4A–D). In men, the corre-
sponding rates were 0.2%, 0.5%, 1.2% and 1.9% in patients and 0.1%, 0.5%,
0.9% and 1.7% in controls. Myocardial infarction in patients with AF oc-
curred less often than stroke and transient ischemic attack and heart
failure, while the incidence in controls was higher than stroke and tran-
sient ischemic attack and heart failure (Table 3). The relative risk
showed only a weak association, indicating a trend towards an
increased risk of myocardial infarction, although this was statistically sig-
niﬁcant only in women older than 65 years and in men 65–74 years.
In patientswith AF, it was found that the incidence rateswere statistically
signiﬁcantly increased in men overall and in the age category 65–
74 years, when compared to women.and controls without other diagnoses in all age categories.
Fig. 4. A-4D risk of myocardial infarction in patients with atrial ﬁbrillation and controls without other diagnoses in all age categories.
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The annual rates of all-cause mortality in women were 0.2%, 0.5%,
1.7% and 5.0% in age categories b55, 55–64, 65–74 and 75–85 years
and 0.3%, 0.5%, 1.3% and 3.6% in controls (Fig. 5A–D). In men, the corre-
sponding rates were 0.2%, 0.7%, 2.3% and 5.9% in patients and in controls
0.2%, 0.7%, 2.0% and 5.1% (Table 2). In total, women had a relative risk
versus controls of 1.4 (95% CI, 1.3 to 1.6) and men 1.2 (95% CI, 1.0 to
1.3) (Table 3). In the different age categories, the strongest association
was seen in women in the age categories of 65–74 and 75–85 years.
In male patients, the incidence rate was increased in all age categories
and was statistically signiﬁcant from age 55 and older, when compared
to women.4. Discussion
In this large and nation-wide matched control study, AF as the one
and only diagnosis at inclusion was not a harmless condition and was
over time associated with increased risk of subsequent cardiovascular
morbidity that differed between age groups and sexes.
To the best of our knowledge, our study cohort represents by far the
largest number of patients with incident AF and no other co-morbidity
at the time of diagnosis. Moreover, this is the ﬁrst study with complete
national coverage of this diagnosis. Strikingly, we found an annual
incidence of stroke or transient ischemic attack of 1.0–1.1% in the age
category between 55 and 64 years in both sexes. While this does notjustify long-term warfarin treatment according to current guidelines,
the comparative efﬁcacy and lower risk of new oral anticoagulation
might result in an advantageous beneﬁt/risk ratio in this group and
thus increase the number of candidates for treatment [21–33].
The two risk scores CHA2DS2-VASc and CHADS2 are intended to
discriminate patients with a high enough risk of stroke to justify
anticoagulation [21,22]. The annual rate of stroke and transient ischemic
attack in patients younger than 55 years of age was 0.5% in women and
0.3% in men and 0.0% and 0.1% in controls. The corresponding risks in
patients and controls between 55 and 64 years of age were 1.1% and
0.3% in women and 1.0% and 0.4% in men. These patients had no dis-
eases other than AF at the time of inclusion, which corresponds to
zero points in CHADS2 and zero points in men and one point in
women in CHA2DS2-VASc. In the risk scores, one point is sufﬁcient to
suggest anticoagulation treatment, except when female sex is the only
risk factor in the CHA2DS2-VASc [23]. In the CHA2DS2-VASc score, one
point corresponds to an annual stroke rate with a range between 0.6%
and 2.0% [22,24–28]. In CHADS2 for a score of one point, the correspond-
ing annual stroke rates are more pronounced and lie between 3.0% and
4.8% [26–28]. Eckman et al. suggested that an annual stroke rate of 0.9%
would justify a change of treatment policy from warfarin to novel
anticoagulation therapy [29]. The annual rates for intracranial bleeding
in studies of novel anticoagulant are between 0.2% and 0.5% in cohorts
where the median ages were between 70 and 73 years, and the mean
values in the CHADS2 score were between 2.1 and 3.5, which are signif-
icantly lower than for warfarin [30–32]. Taillandier et al. have pointed
out that overtreatment occurred in patients with CHA2DS2-VASc
Fig. 5. A-5D risk of all-cause mortality in patients with atrial ﬁbrillation and controls without other diagnoses in all age categories.
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anticoagulation treatment, and the yearly stroke rates were 0.64% in
untreated (mean age 41 years) and 0.69% in treated patients (mean
age 52 years) [33]. In patients with AF between 55 and 65 years of age
andwithout other co-morbidities, the efﬁciency of preventive anticoag-
ulant treatment and the risk for major bleedings are uncertain.
The relative risks and event rates of stroke or transient ischemic
attackwere increased inwomen compared tomen and in all age catego-
ries. These ﬁndings are in line with previous studies and support that
the female gender is given special attention in the risk assessment of
stroke or transient ischemic attack, but they also imply that female
gender alone is sufﬁcient to identify subgroups of patients that could
be candidates for anticoagulation [18,21].
Further, and in contrast to the previous studies, we found heart
failure to be the most common cardiovascular disease in any of the
age categories among patients and controls and observed that the risk
of heart failure versus controls did not differ between women and
men. Given our large cohort compared to earlier, smaller studies and
that the diagnosis of heart failure has a high positive predictive value
in the registries, these ﬁndings seem reasonable. Presumably, patients
without other in-hospital diagnoses at the time of inclusion have a
risk of developing tachycardia-induced heart failure during follow-up.
Regarding myocardial infarction, we observed an increased risk in
both sexes overall but, as concerns the different age categories, an asso-
ciation was seen only in women older than 65 years and in men
between 65 and 74 years of age. This is similar to previous ﬁndingswhere only one study, in which patients had a mean age of 74 years
at inclusion, showed an increased risk of myocardial infarction
(Table 1). In patients with AF in our study, the incidence rate ofmyocar-
dial infarctionwashigher inmen than inwomen, in linewithﬁndings in
patients without atrial ﬁbrillation [34,35]. For all-cause mortality, the
relative risk was statistically signiﬁcant overall in women and men.
However, the relative risk in the various age categories was only in-
creased in women older than 65 years and in men between 65 and
74 years of age. The increased all-cause mortality could reﬂect the
increased risks we found for stroke and heart failure and needs more
investigation.
We chose to include patients up to the age of 85 years and analyze
data in four different age groups. Exclusion and inclusion criteria in ear-
lier studies varied, and the rates of lone or idiopathic AF were between
1.6% and 30%, while the incidence of idiopathic AFwas as high as 67% in
the Paris Protective Study [4–6,8,36,37]. In our previously described
study cohort of 272,186 patients with AF, from which the cohort of
this study was derived, 5% had no other in-hospital diagnoses during
at least the eight years prior to inclusion and one year after inclusion
[2].
In our nationwide study population of patients hospitalized with in-
cident AF, the patients in the 55 to 64 years segment amounted to 2657
individuals, which are 27.9% of the studied cases without other diseases
or 1.0% of the original cohort. Considering that AF can most often be
managed without hospitalization, we assume that the risk ratios in
this study are an underestimation of potential new candidates for
98 T. Andersson et al. / International Journal of Cardiology 177 (2014) 91–99anticoagulation and that a substantial number of patients were not
hospitalized or not even detected owing to asymptomatic AF.4.1. Limitations
The number of confounding factors was greatly reduced by exclu-
sion of all in-hospital diagnoses except AF in patients and controls,
but subjects who are exclusively managed in outpatient care are not
registered in Swedish hospital registries. Especially the diagnosis of
hypertension is suspected to be underestimated since many patients
are only diagnosed and treated in primary care. This possible misclassiﬁ-
cation could also apply to controls. Most likely, we also underestimated
the true national number of AF diagnoses in both patients and
controls.
We have no access to echocardiography examinations due to our
study design that uses the Swedish National Patient Registry. Most pre-
vious studies have not used echocardiography, however, and because
that examination is part of the routine hospital work-up in Sweden,
the majority of patients in our study were most likely examined, thus
considerably reducing the risk of concomitant heart failure [4–8,11,12].
Wehavenodata onmedication records during the studyperiod between
1995 and 2009. A number of patients may have been on anticoagulation
medication despite a formal guideline recommendation, but our data-
base does not provide information on this. Further, the use of anti-
arrhythmic drugs and the possible impact they may have is unknown
to us. Other potential confounders such as smoking, educational level
and socioeconomic status may have affected the relative risk for out-
comes between patients and controls.
The various types of AF, i.e. paroxysmal, persistent or permanent,
might have inﬂuenced the results, but the registry data did not allow
for this differentiation. On the other hand, since the registry allowed
us to identify incident AF, it is likely that a substantial proportion of
patientswere found in an early phase and that some of themprogressed
to persistent and permanent types during the 14 years of follow-up. In
addition, we decided to include atrial ﬂutter, since it often coexists in
patients with AF and the differential diagnosis can be challenging.5. Conclusions
The relative risk of a stroke or a transient ischemic attack and
heart failure was signiﬁcantly higher in patients with AF irrespec-
tive of age and sex. The association of AF with myocardial infarction
and all-cause mortality was weaker. Women were at higher risk of
stroke or transient ischemic attack than men. While agreeing with
current guidelines on anticoagulant treatment in patients 65 years
and older, our study results pointed out that the annual rate of
stroke and transient ischemic attack in men and women between
55 and 64 years was 1.0% and 1.1% and in controls 0.4% and 0.3%, re-
spectively. Our ﬁndings might justify prevention measures if new
oral anticoagulant agents are found to have the same efﬁcacy and
sufﬁcient safety at these ages.Conﬂict of interests
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